Rate of early treatment discontinuation among a community sample of naive hepatitis C patients on Rebetron combination therapy.

被引：0
|
作者：
Belville-Robertson, TL
Brown, KA
Moonka, DK
Mahr, G
Clemensen, LR
Mankato, N
Lucas, MB
Eshelman, AK
机构：
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] ISJ Clin Northridge, N Mankato, MN USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1716
引用
收藏
页码：601A / 601A
页数：1
相关论文
共 50 条
  • [21] Combination therapy with low dose interferon and ribavirin in naive patients with hepatitis C.
    Martin, A
    Canchis, PW
    Tamburro, CH
    Fortwengler, P
    Cecil, B
    Cox, A
    Adler, E
    Miller, B
    Chene, B
    Hiser, M
    HEPATOLOGY, 1999, 30 (04) : 620A - 620A
  • [22] High dose induction therapy with consensus interferon followed by combination therapy with ribavirin for treatment-naive hepatitis C patients
    Kaiser, S
    Kreysel, C
    Hass, H
    Gregor, M
    GASTROENTEROLOGY, 2001, 120 (05) : A383 - A383
  • [23] The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C
    Chemello, L
    Cavalletto, L
    Bernardinello, E
    Guido, M
    Pontisso, P
    Alberti, A
    JOURNAL OF HEPATOLOGY, 1995, 23 : 8 - 12
  • [24] Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results
    Moscarella, S
    Buzzelli, G
    Romanelli, RG
    Monti, M
    Giannini, C
    Careccia, G
    Marrocchi, EM
    Zignego, AL
    LIVER, 1998, 18 (05): : 366 - 369
  • [25] Treatment with amantadine plus ribavirin plus interferon in patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy.
    Ferenci, P
    Stauber, R
    Hackl, F
    Schuetze, K
    Bauer, B
    Datz, C
    GASTROENTEROLOGY, 2000, 118 (04) : A1437 - A1437
  • [26] Systematic review: Evaluation of adherence among treatment naive patients with hepatitis C
    Cano Corral, C.
    Martinez Lopez, I.
    Alarcon Payer, C.
    Martinez Martinez, F.
    PHARMACEUTICAL CARE ESPANA, 2014, 16 (04): : 156 - 161
  • [27] THE COST EFFECTIVENESS OF A NOVEL HIGH PRICED COMBINATION THERAPY FOR HEPATITIS C IN TREATMENT NAIVE GENOTYPE 1 INFECTED PATIENTS
    McGinnis, J. J.
    Hay, J. W.
    VALUE IN HEALTH, 2015, 18 (03) : A238 - A239
  • [28] Continuous combination therapy induces viral clearance in hepatitis C patients who were previous nonresponders to standard combination therapy.
    Lawitz, EJ
    Cantu, NS
    Kadakia, SC
    HEPATOLOGY, 2001, 34 (04) : 583A - 583A
  • [29] Efficacy and tolerability of interferon (Intron A®) plus Ribavirin (Rebetron®) administered daily for two months.: Then thrice weekly interferon (Intron A®) plus Ribavirin (Rebetron®), versus standard thrice weekly administration of Rebetron for the treatment of chronic hepatitis C in patients naive to interferon therapy
    Epstein, MS
    King, CE
    Ravendhran, N
    Finkel, RG
    Lobis, IF
    Laurin, J
    Korman, LY
    Axelrad, AM
    Snow, ND
    Praschak, PM
    HEPATOLOGY, 2000, 32 (04) : 552A - 552A
  • [30] High dose induction therapy with consensus interferon followed by combination therapy with ribavirin for treatment-naive hepatitis C patients.
    Kaiser, S
    Kreysel, C
    Hass, H
    Gregor, M
    HEPATOLOGY, 2001, 34 (04) : 581A - 581A
12345